Latest News in the pharma Industry

Research & Development

Shire submits IND application to FDA for gene therapy candidate SHP654 for treatment of hemophilia A

Shire submits IND application to FDA for gene therapy candidate SHP654 for treatment of hemophilia A

9 Jul 2017

SHP654 aims to deliver sustained protection against bleeds for patients with hemophilia A.

Read more 
Almac Discovery granted Orphan Drug Designation for ALM201 programme in ovarian cancer

Almac Discovery granted Orphan Drug Designation for ALM201 programme in ovarian cancer

7 Jul 2017

ALM201 is a therapeutic peptide developed to mimic some of the properties of the naturally occurring protein FKBPL.

Read more 
Phase III study evaluating safety and efficacy of adjuvant Opdivo in resected melanoma patients meets primary endpoint

Phase III study evaluating safety and efficacy of adjuvant Opdivo in resected melanoma patients meets primary endpoint

6 Jul 2017

Opdivo demonstrates superior recurrence-free survival versus Yervoy in adjuvant setting in CheckMate -238.

Read more 
First patients treated in Phase I/II trial of  NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer

First patients treated in Phase I/II trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer

4 Jul 2017

NOX-A12 has the potential to transform cancer types that are resistant to checkpoint inhibitor therapy into checkpoint inhibitor sensitive tumours

Read more 
Common antimicrobials help patients recover from MRSA abscesses

Common antimicrobials help patients recover from MRSA abscesses

3 Jul 2017

NIAID-funded trial counters current thinking about treatment effectiveness.

Read more 
Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced NSCLC

Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced NSCLC

29 Jun 2017

In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival compared with SOC chemotherapy with maintenance.

Read more 
Researchers develop microneedle patch for flu vaccination

Researchers develop microneedle patch for flu vaccination

28 Jun 2017

The patch can dramatically reduce the cost of vaccination, as self-administration can eliminate the need to have health workers oversee the process.

Read more 
Merck's anacetrapib meets primary endpoint

Merck's anacetrapib meets primary endpoint

28 Jun 2017

Company to consider whether to file new drug applications with the FDA and other regulatory agencies.

Read more 
Cladribine Tablets receives positive CHMP opinion for treatment of relapsing forms of MS

Cladribine Tablets receives positive CHMP opinion for treatment of relapsing forms of MS

25 Jun 2017

Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical trials.

Read more 
Pfizer receives expanded Health Canada approval for Ibrance in HR+, HER2- metastatic breast cancer

Pfizer receives expanded Health Canada approval for Ibrance in HR+, HER2- metastatic breast cancer

25 Jun 2017

New indication supported by results of Phase III PALOMA-3 Trial of Ibrance in combination with fulvestrant.

Read more 
Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by CHMP

Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by CHMP

23 Jun 2017

If approved, Imraldi will be the third anti-TNF biosimilar in Biogen’s portfolio in Europe.

Read more 
Novartis achieves regulatory milestone for AMG 334 in migraine prevention with EMA filing acceptance

Novartis achieves regulatory milestone for AMG 334 in migraine prevention with EMA filing acceptance

21 Jun 2017

AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance.

Read more